PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Trough-Guided Voriconazole Dose Adjustment: Population PK Model Validated in 67 Patients

voriconazoletriazole antifungalpopulation pharmacokineticsNONMEMtherapeutic drug monitoringMonte Carlo simulationinvasive fungal infectiondose optimizationC-reactive proteincreatinine clearanceomeprazoleretrospective study Pharmacokinetics / TDM

Background Information

New model boosts voriconazole target concentration achievement by 44.74%.

Optimizing voriconazole dosing through pharmacokinetic modeling can enhance therapeutic outcomes and minimize toxicity. The model showed that adjusted dosing improved target plasma concentration achievement from 46.3% to 91.04% in a validation cohort. This study provides a dosing adjustment model for voriconazole that can significantly improve therapeutic drug monitoring outcomes, but the sample size was relatively small. Pharmacokinetic model-based dosing significantly increases achievement of target voriconazole plasma concentrations.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jiang L, Lin Z

Citation: Jiang L, Lin Z Population pharmacokinetic modeling of voriconazole based on real-world data for dosing regimen optimization. Frontiers in pharmacology. 2026;17:1979373. doi:10.3389/fphar.2026.1979373

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.